Braeburn's Buprenorphine Bid: Eight Dosing Options Part Of "All Hands On Deck" Approach
Executive Summary
With an FDA decision on its buprenorphine injection expected by Jan. 19, Scrip spoke with Braeburn executives at J.P. Morgan about the company's justification for four once-weekly and four once-monthly doses, competition in the opioid use disorder (OUD) market and the need for more OUD therapies.
You may also be interested in...
While You Were Out: News In Brief
Updates from the holiday season include a Phase III failure for Pfizer's MRSA vaccine, AbbVie's submission of upadacitinib for rheumatoid arthritis and several year-end US approvals and FDA actions.
Indivior's Once-Monthly Buprenorphine Clears US FDA With Box Warning, REMS
Launch targeted for first quarter 2018 at price of $1,580 per monthly dose. Post-market requirements include study of 300 mg dose and use as initial treatment. Indivior also following health outcomes.
Opioid Treatments Could Get Survival Claim As US FDA Develops Protocol
Commissioner Gottlieb announces several actions in the works to promote development of new treatments for opioid addiction, including guidance on how to establish novel endpoints.
Need a specific report? 1000+ reports available
Buy Reports